TY  - JOUR
A1  - Mössner, Rotraut
A1  - Thaçi, Diamant
A1  - Mohr, Johannes
A1  - Pätzold, Sylvie
A1  - Bertsch, Hans Peter
A1  - Krüger, Ullrich
A1  - Reich, Kristian
T1  - Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis : report on five cases
T2  - Archives of dermatological research
N2  - Infliximab is a monoclonal antibody directed against TNF-alpha. It has been approved for use in rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriatic arthritis and plaque-type psoriasis. In case reports, positive effects on pustular variants of psoriasis have also been reported. However, paradoxically, manifestation of pustular psoriasis and plaque-type psoriasis has been reported in patients treated with TNF antagonists including infliximab for other indications. Here, we report on 5 patients with chronic plaque-type psoriasis who developed palmoplantar pustulosis during or after discontinuation of infliximab therapy. In two of the five cases, manifestation of palmoplantar pustulosis was not accompanied by worsening of plaque-type psoriasis. Possibly, site-specific factors or a differential contribution of immunological processes modulated by TNF inhibitors to palmoplantar pustulosis and plaque-type psoriasis may have played a role.
KW  - TNF
KW  - Antagonist
KW  - Infliximab
KW  - Pustulosis
KW  - Psoriasis
Y1  - 2008
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/6009
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30-60222
SN  - 1432-069X
SN  - 0340-3696
N1  - Open Access: This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
VL  - 300
IS  - 3
SP  - 101
EP  - 105
PB  - Springer
CY  - Berlin ; Heidelberg ; New York
ER  -